Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Receivables (2016 - 2026)

Akebia Therapeutics has reported Receivables over the past 10 years, most recently at $47.5 million for Q4 2025.

  • Quarterly Receivables rose 30.66% to $47.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $47.5 million through Dec 2025, up 30.66% year-over-year, with the annual reading at $47.5 million for FY2025, 30.66% up from the prior year.
  • Receivables was $47.5 million for Q4 2025 at Akebia Therapeutics, down from $66.2 million in the prior quarter.
  • Over five years, Receivables peaked at $138.6 million in Q2 2022 and troughed at $18.7 million in Q1 2023.
  • The 5-year median for Receivables is $37.1 million (2021), against an average of $45.1 million.
  • Year-over-year, Receivables soared 717.26% in 2021 and then crashed 85.88% in 2023.
  • A 5-year view of Receivables shows it stood at $19.8 million in 2021, then surged by 113.12% to $42.2 million in 2022, then increased by 1.04% to $42.6 million in 2023, then dropped by 14.65% to $36.4 million in 2024, then skyrocketed by 30.66% to $47.5 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Receivables are $47.5 million (Q4 2025), $66.2 million (Q3 2025), and $72.8 million (Q2 2025).